DDInter1747 DDInter1352
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
Osimertinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tazemetostat
Osimertinib {u} may lead to a major life threatening interaction when taken with {v} Tetrabenazine
Osimertinib {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Osimertinib may lead to a major life threatening interaction when taken with Tetrabenazine
Osimertinib may lead to a major life threatening interaction when taken with Entrectinib